Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer
Purpose of the study. Assessment of albumin and endogenous intoxication levels in patients with locally advanced cervical cancer receiving immunotherapy with dendritic cell vaccine.Materials and methods. The study included 27 patients with advanced cervical cancer (CC) divided into 3 groups: 1) pati...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2022-06-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/737 |
| _version_ | 1826559190226698240 |
|---|---|
| author | I. A. Goroshinskaya A. P. Menshenina E. M. Frantsiyants I. V. Kaplieva T. I. Moiseenko E. V. Verenikina L. A. Nemashkalova |
| author_facet | I. A. Goroshinskaya A. P. Menshenina E. M. Frantsiyants I. V. Kaplieva T. I. Moiseenko E. V. Verenikina L. A. Nemashkalova |
| author_sort | I. A. Goroshinskaya |
| collection | DOAJ |
| description | Purpose of the study. Assessment of albumin and endogenous intoxication levels in patients with locally advanced cervical cancer receiving immunotherapy with dendritic cell vaccine.Materials and methods. The study included 27 patients with advanced cervical cancer (CC) divided into 3 groups: 1) patients receiving dendritic cell vaccine (DCV) during primary chemoradiation treatment; 2) patients with the disease progression receiving DCV during second‑line chemotherapy; 3) patients with advanced disease with contraindications for chemo‑radiation treatment receiving DCV only. The comparison group included 20 healthy women. All groups were tested for levels of medium‑weight molecules (MWM254 and MWM280), total and effective concentrations of albumin (TCA and ECA), toxicity index (TI) characterizing the sorption capacity of albumin, and the coefficient of intoxication (CI) reflecting the balance between the accumulation and binding of toxic ligands.Results. Initial elevation of MWM was observed in all patients. Levels of MWM254 were the highest in patients with progression. TI in patients with primary and progressive CC was increased before the treatment by 1.7 and 2.2 times, and after CT (without DCV) – by 2.6 and 3.8 times. In group 3, TI was increased by 4 times, and CI by 2.5 times, being 81 % higher than in group 1. In primary patients, TI after 6 and 7 DCVs was similar to the normal values, and CI was increased during the treatment because of the accumulation of MWM254 due to disintegration of tumor masses in these patients, and then it was normalized after 7 DCVs. CI in patients of groups 2 and 3 decreased after each DCV session. 4 and more DCVs restored the functional activity of albumin and normalized the MWM content.Conclusion. Administration of DCV (at least 7–8 sessions) in CC patients receiving anticancer treatment or as monotherapy decreases endotoxicosis and restores detoxification capacity of albumin. |
| first_indexed | 2024-04-10T01:25:39Z |
| format | Article |
| id | doaj.art-0db06f5ac7ec4652871b8154285d2481 |
| institution | Directory Open Access Journal |
| issn | 2410-1893 |
| language | Russian |
| last_indexed | 2025-03-14T08:56:27Z |
| publishDate | 2022-06-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj.art-0db06f5ac7ec4652871b8154285d24812025-03-02T12:44:11ZrusQUASAR, LLCИсследования и практика в медицине2410-18932022-06-0192344910.17709/2410-1893-2022-9-2-3445Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancerI. A. Goroshinskaya0A. P. Menshenina1E. M. Frantsiyants2I. V. Kaplieva3T. I. Moiseenko4E. V. Verenikina5L. A. Nemashkalova6National Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyPurpose of the study. Assessment of albumin and endogenous intoxication levels in patients with locally advanced cervical cancer receiving immunotherapy with dendritic cell vaccine.Materials and methods. The study included 27 patients with advanced cervical cancer (CC) divided into 3 groups: 1) patients receiving dendritic cell vaccine (DCV) during primary chemoradiation treatment; 2) patients with the disease progression receiving DCV during second‑line chemotherapy; 3) patients with advanced disease with contraindications for chemo‑radiation treatment receiving DCV only. The comparison group included 20 healthy women. All groups were tested for levels of medium‑weight molecules (MWM254 and MWM280), total and effective concentrations of albumin (TCA and ECA), toxicity index (TI) characterizing the sorption capacity of albumin, and the coefficient of intoxication (CI) reflecting the balance between the accumulation and binding of toxic ligands.Results. Initial elevation of MWM was observed in all patients. Levels of MWM254 were the highest in patients with progression. TI in patients with primary and progressive CC was increased before the treatment by 1.7 and 2.2 times, and after CT (without DCV) – by 2.6 and 3.8 times. In group 3, TI was increased by 4 times, and CI by 2.5 times, being 81 % higher than in group 1. In primary patients, TI after 6 and 7 DCVs was similar to the normal values, and CI was increased during the treatment because of the accumulation of MWM254 due to disintegration of tumor masses in these patients, and then it was normalized after 7 DCVs. CI in patients of groups 2 and 3 decreased after each DCV session. 4 and more DCVs restored the functional activity of albumin and normalized the MWM content.Conclusion. Administration of DCV (at least 7–8 sessions) in CC patients receiving anticancer treatment or as monotherapy decreases endotoxicosis and restores detoxification capacity of albumin.https://www.rpmj.ru/rpmj/article/view/737cervical cancerdendritic cell vaccineendogenous intoxicationmedium-weight moleculestoxicity indexcoefficient of intoxication |
| spellingShingle | I. A. Goroshinskaya A. P. Menshenina E. M. Frantsiyants I. V. Kaplieva T. I. Moiseenko E. V. Verenikina L. A. Nemashkalova Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer Исследования и практика в медицине cervical cancer dendritic cell vaccine endogenous intoxication medium-weight molecules toxicity index coefficient of intoxication |
| title | Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer |
| title_full | Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer |
| title_fullStr | Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer |
| title_full_unstemmed | Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer |
| title_short | Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer |
| title_sort | endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer |
| topic | cervical cancer dendritic cell vaccine endogenous intoxication medium-weight molecules toxicity index coefficient of intoxication |
| url | https://www.rpmj.ru/rpmj/article/view/737 |
| work_keys_str_mv | AT iagoroshinskaya endotoxemiainimmunotherapywithdendriticcellvaccineinpatientswithadvancedcervicalcancer AT apmenshenina endotoxemiainimmunotherapywithdendriticcellvaccineinpatientswithadvancedcervicalcancer AT emfrantsiyants endotoxemiainimmunotherapywithdendriticcellvaccineinpatientswithadvancedcervicalcancer AT ivkaplieva endotoxemiainimmunotherapywithdendriticcellvaccineinpatientswithadvancedcervicalcancer AT timoiseenko endotoxemiainimmunotherapywithdendriticcellvaccineinpatientswithadvancedcervicalcancer AT evverenikina endotoxemiainimmunotherapywithdendriticcellvaccineinpatientswithadvancedcervicalcancer AT lanemashkalova endotoxemiainimmunotherapywithdendriticcellvaccineinpatientswithadvancedcervicalcancer |